Esperion Therapeutics (ESPR) Other Operating Expenses (2020 - 2026)

Esperion Therapeutics has reported Other Operating Expenses for 7 years, with the latest figure at $34.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 9.62% year-over-year to $34.6 million; the trailing twelve-month figure through Mar 2026 stood at $132.3 million (up 210.91% YoY), and the FY2025 full-year result was $129.2 million, up 191.84% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $34.6 million, up from $27.9 million in the prior quarter.
• The five-year high for Other Operating Expenses was $41.3 million in Q3 2025, with the low at -$217.2 million in Q4 2023.
• Historically, Other Operating Expenses has averaged -$8.0 million across 5 years, with a median of $11.7 million in 2023.
• Annual changes were most pronounced in 2022 — Other Operating Expenses surged 409.78% — and 2023, when it slumped 5320.62%.
• Esperion Therapeutics' Other Operating Expenses stood at $4.2 million in 2022, then tumbled by 5320.62% to -$217.2 million in 2023, then advanced by 15.42% to -$183.7 million in 2024, then jumped by 115.16% to $27.9 million in 2025, then advanced by 24.12% to $34.6 million in 2026.
• The last three Other Operating Expenses figures came in at $34.6 million (Q1 2026), $27.9 million (Q4 2025), and $41.3 million (Q3 2025), per Business Quant data.